Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer.
This article on permanent iodine-125 seed prostate brachytherapy reviews the techniques, results, and patient selection issues for early prostate cancer. The long-term 10 y results of brachytherapy from Seattle, and their reproducibility in other centres both in the USA and UK are reported. The use of hormone therapy in brachytherapy and the value of combining external beam radiotherapy with a brachytherapy implant are discussed. Reviewed comparative data show the similarity of biochemical survival in patients treated with brachytherapy, radical prostatectomy, and external beam radiotherapy. The role of brachytherapy as a first-line treatment option for patients with prostate cancer is demonstrated.
Langley
S E M
SE
Department of Urology, St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford GU2 5XX, UK. stephen.langley@dial.pipex.com
Laing
R W
RW
D001918:Brachytherapy / Q000009:adverse effects; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D015203:Reproducibility of Results
D007457:Iodine Radioisotopes